KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:开放图源暂不可得 入排置信度 0.95

[Neoadjuvant chemoradiotherapy followed by active surveillance versus standard surgery for oesophageal cancer (SANO-trial): a phase 3 multicentre stepped-wedge cluster-randomised noninferiority trial].

B J van der Wilk, S S G Gangaram Panday, B M Eyck, S M Lagarde, B P L Wijnhoven, J J B van Lanschot, B Mostert, M C W Spaander, C Rosman, E A Kouwenhoven

Ned Tijdschr Geneeskd 169 D8721

PMID41725589
PMCID-
DOI-
发表日期2026-02-23
入排依据:The record describes a randomized Phase III trial with a primary time-to-event endpoint (OS) and reports results. However, the intervention under investigation is a management strategy (active surveillance) versus standard surgery following neoadjuvant chemoradiotherapy. The eligibility criterion of a 'drug-containing intervention' is not met, as the trial does not randomize patients to different drug regimens.
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。
摘要

摘要

OBJECTIVE: To investigate whether active surveillance is non-inferior to standard surgery for patients with a complete clinical response (CCR) after neoadjuvant chemoradiotherapy (nCRT) for oesophageal cancer. DESIGN: A multicentre, stepped-wedge cluster-randomised non-inferiority trial in twelve Dutch hospitals. METHOD: Patients with locally advanced oesophageal cancer and CCR after nCRT (defined by biopsies, endoscopic ultrasound, and PET-CT ) were assigned to active surveillance or standard surgery . The primary endpoint was two-year overall survival. Non-inferiority was defined as ≤15% difference in survival. RESULTS: Of 1,115 screened patients, 309 were included (198 active surveillance, 111 standard surgery). Two-year survival was 74% for active surveillance and 71% for surgery. The hazard ratio for survival was 1.14 (95%-CI: 0.74-1.78). No differences in postoperative complications or mortality were observed. CONCLUSION: Active surveillance is non-inferior to standard surgery after two years for patients with CCR post-nCRT. Further follow-up is needed to confirm long-term efficacy and safety.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。